Current osteoporosis medications reduce fractures significantly but have rare and serious
adverse effects (osteonecrosis of the jaw, atypical femoral fractures) that may limit their …

Highlights•Odanacatib is a new antiresorptive therapy with documented anti-fracture
efficacy.•Romosozumab is a new bone anabolic treatment that also inhibits resorption.• …

Osteoporosis and fragility fractures are relevant health issues because of their impact in
terms of morbidity, mortality, and socioeconomic burden. Despite this alarming scenario …

Osteoporosis is characterized by low bone mass and qualitative structural abnormalities of
bone tissue, leading to increased bone fragility that results in fractures. Pharmacological …

New anti-osteoporotic agents have been developed, potentially enriching the therapeutic
armamentarium. Currently available osteoanabolic therapies are the parathyroid hormone …

Since the identification of osteoporosis as a major health issue in aging populations and the
subsequent development of the first treatment modalities for its management, considerable …

Introduction: Pharmacological options to address the imbalance between bone resorption
and accrual in osteoporosis include anti-resorptive and osteoanabolic agents. Unique …

Osteoporosis affects 1.2 million Australians and, in 2012, fractures due to osteoporosis and
osteopenia in Australians aged over 50 years cost $2.75 billion. Even minor minimal trauma …

There has been substantial progress in the management of patients with osteoporosis and
the prevention of osteoporotic fractures. Currently available strong anti-resorptive agents are …

The field of osteoporosis may be coming full circle, and that is not good for the millions of
older women and men who will suffer painful and disabling spine and hip fractures …